

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A method for [[treating]] reducing snoring in a patient in need thereof, comprising administering to [[a]] the patient an agent for treating symptoms of hyper-acidity or gastro-intestinal reflux disease (GERD).
- 2-4. **(Canceled)**
5. **(Previously Presented)** The method of claim 1, wherein said agent is an H₂ histamine receptor antagonist, an inhibitor of H⁺, K⁺ ATPase, a proton pump inhibitor, a Bismuth compound, an antacid, a synthetic analog of somatostatin, an antiemetic agent, a sucralfate, prostaglandin analog, a muscarinic cholinergic antagonist, a D₂ antagonist, a chenodeoxycholic acid, an ursodeoxycholic acid, or a pancreatic enzyme preparation.
6. **(Previously Presented)** The method of claim 1, wherein said agent is an inhibitor of gastric secretion.
7. **(Withdrawn, Previously Presented)** The method of claim 6, wherein said inhibitor is an H₂ histamine receptor antagonist selected from TAGAMETTM (cimetidine), ZANTACTM (ranitidine), PEPCIDTM (famotidine), or AXIDTM (nizatidine).
8. **(Previously Presented)** The method of claim 6, wherein said inhibitor is an H⁺, K⁺ ATPase selected from PREVACIDTM (lansoprazole), NEXIUMTM (esomeprazole magnesium), or PRILOSECTM (omeprazole).
9. **(Previously Presented)** The method of claim 6, wherein said inhibitor is PREVACIDTM (lansoprazole).
10. **(Withdrawn, Previously Presented)** The method of claim 6, wherein said inhibitor is PROTONIX[®] (pantoprazole sodium) or ACIPHEX[®] (rabeprazole sodium or pariprazole).
11. **(Previously Presented)** The method of claim 6, wherein said inhibitor is a compound or a pharmaceutical composition represented by any of formulas I-XVIII or salts thereof.
- 12-17. **(Canceled)**